We hypothesize patients with TMD will have elevated levels of inflammatory (IL-1β, TNF-α, IL-6, IL-17A), pain (SP, CGRP), and enzymatic biomarker of tissue destruction (PAD-4) in their synovial and whole saliva fluids, which are associated to their clinical diagnostic markers. This evidence concerns the gene TNF and temporomandibular joint disorder.